IN2014MN01778A - - Google Patents

Info

Publication number
IN2014MN01778A
IN2014MN01778A IN1778MUN2014A IN2014MN01778A IN 2014MN01778 A IN2014MN01778 A IN 2014MN01778A IN 1778MUN2014 A IN1778MUN2014 A IN 1778MUN2014A IN 2014MN01778 A IN2014MN01778 A IN 2014MN01778A
Authority
IN
India
Prior art keywords
prodrugs
diketone
monosubstituted
vitamin
plasma
Prior art date
Application number
Inventor
Mona Moller
Marcel Sandberg
Inger Reidun Aukrust
Original Assignee
Kappa Bioscience As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kappa Bioscience As filed Critical Kappa Bioscience As
Publication of IN2014MN01778A publication Critical patent/IN2014MN01778A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/40—Succinic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/098—Esters of polyphosphoric acids or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to prodrugs of vitamin K2 in particular prodrugs of MK 7 in which the diketone is converted to a monosubstituted or disubstituted ester type derivative. These compounds are shown to give MK-7 in plasma.
IN1778MUN2014 2012-03-02 2013-03-04 IN2014MN01778A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1203705.7A GB201203705D0 (en) 2012-03-02 2012-03-02 Prodrugs
PCT/EP2013/054298 WO2013128037A1 (en) 2012-03-02 2013-03-04 Prodrugs of vitamine k

Publications (1)

Publication Number Publication Date
IN2014MN01778A true IN2014MN01778A (en) 2015-07-03

Family

ID=46003017

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1778MUN2014 IN2014MN01778A (en) 2012-03-02 2013-03-04

Country Status (10)

Country Link
US (2) US9512153B2 (en)
EP (1) EP2819982B1 (en)
CN (1) CN104395273A (en)
AU (1) AU2013224857B2 (en)
DK (1) DK2819982T3 (en)
GB (1) GB201203705D0 (en)
HU (1) HUE029261T2 (en)
IN (1) IN2014MN01778A (en)
PL (1) PL2819982T3 (en)
WO (1) WO2013128037A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203705D0 (en) 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
GB201314245D0 (en) * 2013-08-08 2013-09-25 Kappa Bioscience As Provitamins
CN106455667A (en) 2014-05-05 2017-02-22 巴斯夫欧洲公司 Fat-soluble vitamin preparations
CN107660202B (en) 2015-03-27 2021-12-24 大日本住友制药肿瘤公司 Water-soluble prodrugs
EP3686182A4 (en) 2017-09-22 2021-06-09 Sumitomo Dainippon Pharma Co., Ltd. WATER-SOLUBLE CHEMICALLY ACTIVATED MEDICINAL PRODUCT
KR20210018423A (en) 2018-06-08 2021-02-17 에피존 파마 인코포레이티드 Methods and compositions for preventing or treating tissue calcification
WO2019237054A1 (en) 2018-06-08 2019-12-12 Epizon Pharma, Inc. Methods and compositions for preventing or treating calciphylaxis
CA3111108A1 (en) 2018-09-12 2020-03-19 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment
JP7394433B2 (en) * 2019-03-19 2023-12-08 学校法人福岡大学 Vitamin K preparations applied under light exposure, external skin preparations, eye drops, and eye ointments using the same
JP7658584B2 (en) 2019-05-23 2025-04-08 マサチューセッツ インスティテュート オブ テクノロジー Ligand discovery and gene delivery via retroviral surface display
US12103914B2 (en) * 2020-12-30 2024-10-01 Epizon Pharma, Inc. Compositions of biologically active menaquinol derivatives and methods of treatment
US11912654B2 (en) 2021-09-03 2024-02-27 Synergia Life Sciences Pvt. Ltd. Process for stereospecific synthesis of vitamin K2 and its novel intermediates
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
WO2023129141A1 (en) * 2021-12-28 2023-07-06 Epizon, Inc. Compositions of biologically active menaquinol derivatives and methods of treatment
KR20250036741A (en) * 2022-05-30 2025-03-14 에피존 파마 인코포레이티드 Pegylated menaquinol compositions and methods of treatment
CN119300813A (en) 2022-05-31 2025-01-10 南丹麦大区 Vitamin K2 for the treatment of coronary artery calcification (CAC)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2456686A (en) 1944-05-11 1948-12-21 President & Board Of Trustees Process for obtaining vitamink compounds
GB893172A (en) 1959-10-20 1962-04-04 Roche Products Ltd A process for the manufacture of phosphoric acid esters and novel phosphoric acid esters
US3127434A (en) * 1959-10-20 1964-03-31 Hoffmann La Roche Dihydrovitamin k monophosphate compounds and preparation thereof
CH575904A5 (en) 1972-02-16 1976-05-31 Eisai Co Ltd
GB1426769A (en) * 1972-12-04 1976-03-03 Eisai Co Ltd Process for the production of hydroquinone derivatives
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US8178516B2 (en) 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
EP0679394B1 (en) 1994-04-28 1998-01-14 Eisai Co., Ltd. Menatetronome derivative as antiarteriosclerotic agent
JPH1035256A (en) 1996-07-18 1998-02-10 Denso Corp Vehicular heater
DE19964116A1 (en) 1999-12-30 2001-07-05 Liebscher Dierck H Increasing bioavailability of magnesium ions by co-administration of vitamin K, allowing reduction of dosage in the treatment of magnesium deficiency syndrome
WO2006080463A1 (en) * 2005-01-28 2006-08-03 Fukuoka University Therapeutic agent for cancer and recurrence preventive each containing vitamin k hydroquinone derivative
US20080220094A1 (en) 2006-11-01 2008-09-11 Wyeth Compositions and methods for the treatment and/or prevention of osteoporosis
EP2060256A1 (en) 2007-11-16 2009-05-20 Gnosis S.p.A. Pharmaceutical and nutraceutical compositions based on menaquinols
GB0817528D0 (en) 2008-09-24 2008-10-29 Syntavit As Process
EP2575796A1 (en) 2010-06-03 2013-04-10 Mahmut Bilgic Formulations comprising calcium, vitamin d and vitamin k for osteoporosis
EP2709460A1 (en) 2011-05-20 2014-03-26 Friesland Brands B.V. Composition comprising vitamin k2
GB201203705D0 (en) 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
CN103142568B (en) 2013-03-11 2015-03-11 昆明邦宇制药有限公司 Calcium acetate-vitamin K pharmaceutical preparation and preparation method thereof

Also Published As

Publication number Publication date
EP2819982B1 (en) 2016-09-14
EP2819982A1 (en) 2015-01-07
CN104395273A (en) 2015-03-04
US10159687B2 (en) 2018-12-25
US20170079994A1 (en) 2017-03-23
GB201203705D0 (en) 2012-04-18
WO2013128037A1 (en) 2013-09-06
PL2819982T3 (en) 2017-01-31
US9512153B2 (en) 2016-12-06
HUE029261T2 (en) 2017-02-28
AU2013224857A1 (en) 2014-09-25
AU2013224857B2 (en) 2016-03-17
US20150031651A1 (en) 2015-01-29
DK2819982T3 (en) 2016-11-14

Similar Documents

Publication Publication Date Title
IN2014MN01778A (en)
EP2991935A4 (en) Production of phosphate compounds from materials containing phosphorus and at least one of iron and aluminium
UY33735A (en) ANTIVIRAL COMPOUNDS
CR20150120A (en) NEW BICYCLE DERIVATIVES
NZ730134A (en) Substituted tricyclic compounds as fgfr inhibitors
PH12015502546A1 (en) 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient
MX376793B (en) Phosphoric ester preparations with reduced hygroscopicity
AU2012270029A8 (en) Compositions and methods for modulating a kinase
WO2012154837A9 (en) The use of ketone esters for prevention of cns oxygen toxicity
MX365621B (en) New combination.
MX362752B (en) Morphic forms of hexadecyloxypropyl-phosphonate esters.
WO2013173004A8 (en) Radiopharmaceutical synthesis methods
IN2014DN06738A (en)
EP3177297A4 (en) Compositions relating to vitamin d
PT2812332T (en) Methods for the preparation of hiv attachment inhibitor piperazine prodrug compound
MX2013000539A (en) New formulations of 14 - epi -analogues of vitamin d.
IN2015DN00725A (en)
AU2013347232A8 (en) 3-Aminocyclopentane carboxamide derivatives
IN2014DN07410A (en)
MX2012014071A (en) Stable pharmaceutical composition for treating osteoporosis.
IN2014MN02254A (en)
MX354501B (en) Perfuming ingredient of the galbanum family.
IN2015DN02646A (en)
AP2014007760A0 (en) Stabilized pharmaceutical formulations of a potentHCV inhibitor
IN2015DN02647A (en)